Roy Buchanan
Stock Analyst at JMP Securities
(4.71)
# 164
Out of 5,051 analysts
71
Total ratings
57.97%
Success rate
49.68%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $97.64 | +77.18% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $32.11 | +18.34% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $10.30 | +210.68% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $10.91 | +129.15% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.79 | +269.39% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.27 | +89.75% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.14 | +75.35% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.29 | +686.03% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $53.28 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $2.94 | +36.05% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $2.06 | +579.61% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $99.61 | -66.87% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.61 | +8.46% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $832.35 | -46.18% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $11.16 | +43.37% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.44 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $97.64
Upside: +77.18%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $32.11
Upside: +18.34%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $10.30
Upside: +210.68%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $10.91
Upside: +129.15%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.79
Upside: +269.39%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.27
Upside: +89.75%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.14
Upside: +75.35%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.29
Upside: +686.03%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $53.28
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $2.94
Upside: +36.05%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $2.06
Upside: +579.61%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $99.61
Upside: -66.87%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.61
Upside: +8.46%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $832.35
Upside: -46.18%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $11.16
Upside: +43.37%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -